|
| 36566079 | Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. | | 2023 |
| 37567205 | Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random | | 2023 |
| 36968959 | Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks. | Open Forum Infect Dis | 2023 |
| 36648627 | Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. | | 2023 |
| 35064851 | Utility and Impact of the Implementation of Same-Day, Self-administered Electronic Patient-Reported Outcomes Assessments in Routine HIV Care in two North American Clinics. | AIDS and Behavior | 2022 |
| 35657826 | Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). | PLoS One | 2022 |
| 36090124 | Risk Factors for Suboptimal Adherence Identified by Patient-Reported Outcomes Assessments in Routine HIV Care at 2 North American Clinics. | Patient Preference and Adherence | 2022 |
| 35493119 | Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. | Open Forum Infect Dis | 2022 |
| 34397746 | Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. | J Acquir Immune Defic Syndr | 2021 |
| 33582300 | New Proteomic Signatures to Distinguish Between Zika and Dengue Infections. | Mol Cell Proteomics | 2021 |
| 34115650 | Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. | AIDS | 2021 |
| 34162752 | The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. | Sci Transl Med | 2021 |
| 33946085 | Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. | AIDS | 2021 |
| 33043969 | Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1. | Clinical Infectious Diseases | 2021 |
| 32724674 | Real-World Experience with Dolutegravir-Based Two-Drug Regimens. | AIDS Research and Treatment | 2020 |
| 31995556 | HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. | PLoS ONE | 2020 |
| 31879782 | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study. | Clinical Infectious Diseases | 2020 |
| 31769793 | A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. | Clinical Infectious Diseases | 2020 |
| 32796830 | Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. | Nature Communications | 2020 |
| 31533539 | Patient-reported tolerability and acceptability of cabotegravirâ¿¿+â¿¿rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. | HIV Research and Clinical Practice | 2019 |
| 31291153 | Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses. | Hum Vaccin Immunother | 2019 |
| 31068270 | Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. | Lancet HIV | 2019 |
| 31305329 | Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. | AIDS | 2019 |
| 29368537 | Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. | AIDS Research and Human Retroviruses | 2018 |
| 28259776 | Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i | Lancet HIV,The | 2017 |
| 29091724 | Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. | PLoS One | 2017 |
| 28259777 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. | Lancet HIV,The | 2017 |
| 27865306 | Nocardia Bacteremia and Endocarditis in a Patient With a Sulfa Allergy. | | 2016 |
| 27025835 | 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. | Clin Infect Dis | 2016 |
| 27159225 | Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. | Journal of acquired immune deficiency syndromes (1999) | 2016 |
| 26627107 | Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. | J Acquir Immune Defic Syndr | 2016 |
| 26196502 | Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. | N Engl J Med | 2015 |
| 25585528 | The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects. | HIV Medicine | 2015 |
| 25321146 | Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. | Antiviral Therapy | 2015 |
| 25437129 | Peptostreptococcus endocarditis presenting as lumbar discitis in an immunocompromised patient. | | 2015 |
| 25122785 | Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. | Journal of Virology | 2014 |
| 25664240 | Origin of the dengue virus outbreak in Martin County, Florida, USA 2013. | Virology Reports | 2014 |
| 25397568 | Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor. | Journal of the International AIDS Society | 2014 |
| 25433666 | Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment. | HIV Clinical Trials | 2014 |
| 24702798 | Paradoxical immune reconstitution inflammatory syndrome presenting as acute respiratory distress syndrome in a non-HIV immunosuppressed sarcoidosis patient. | International Journal of Rheumatic Diseases | 2014 |
| 23589672 | Interleukin-7 promotes HIV persistence during antiretroviral therapy. | Blood | 2013 |
| 24081593 | Catastrophic antiphospholipid syndrome (CAPS) induced by influenza A virus subtype H1N1. | BMJ Case Reports | 2013 |
| 23845685 | Spinal osteomyelitis due to Mycobacterium fortuitum in a former intravenous drug user. | BMJ Case Reports | 2013 |
| 23830355 | Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. | Lancet, The | 2013 |
| 21051598 | The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. | Science | 2010 |
| 11181136 | Genitourinary tuberculosis after renal transplantation: report of 3 cases and review. | Clinical Infectious Diseases | 2001 |